Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NCFB). The US regulator cleared DPP1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results